Cipla UK subsidiary to infuse EUR 15 million in Ethris
Mumbai: Cipla Limited has announced that its wholly-owned UKsubsidiary, Cipla (EU) Limited has signed definitive agreements for equityinvestment of EUR 15 million in Ethris GmbH. The investment will facilitate a long-term strategic partnership between Cipla andEthris for the development of messenger RNA (mRNA)-based therapies and fast-trackCipla's participation in the mRNA space, enabling it to provide access to cutting-edge solutions developed by Ethris for the developing countries.
A collaboration agreement is signed concurrently with the definitive agreement,which paves a path to market Ethris' innovative portfolio in Cipla's key emergingmarkets.The transaction is expected to get completed within 60 days from the date of signingof the agreement or such other time period as may be mutually agreed between theparties in writing and shall be subject to completion of necessary regulatoryformalities.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.